Agios Pharmaceuticals, Inc. Overview
AGIO market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
AGIO price chart · 1M
- O
- 28.52
- H
- 29.41
- L
- 28.51
- C
- 29.37
- Vol
- 27,876.00
Daily history from Jan 4, 2016
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $28.52
- Previous Close
- $28.18
- Day High
- $29.41
- Day Low
- $28.51
- 52 Week High
- $46.00
- 52 Week Low
- $22.25
- 7 Day Return
- -3.80%
- 30 Day Return
- -7.67%
- 90 Day Return
- -9.94%
- 1 Year Return
- -27.04%
- Daily Notional Volume
- $818.7K Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$7.12 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.66 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -418.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $22.24 – $46.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.9B · P/B 1.33 · P/S 19.05.
Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.
10 captured
Decision & ScoreThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.
Trend & Pattern EvidenceThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.
Sector Peer RankingThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.
AI-selected reference, checked against source evidence · Evidence observed
Frequently Asked QuestionsSource-linked answers to common questions about this asset. Check the evidence observation date and whether the reference was reviewed by a person.
- What business does AGIOS PHARMACEUTICALS, INC. operate?
- Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias.
- Which industry is AGIOS PHARMACEUTICALS, INC. classified in?
- The SEC company record classifies AGIOS PHARMACEUTICALS, INC. under Pharmaceutical Preparations. This filing classification provides industry context alongside the provider's business description.
What to WatchAI-assisted topics for further research about this asset. These are educational prompts, not trading signals or recommendations.
- Business activities described in the company reference
- Original company disclosures and industry classification